Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

18

Revenue 2017

Epclusa

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Epclusa was produced by Gilead Sciences.

Gilead launches European hep C awareness drive

Gilead launches European hep C awareness drive New drugs, such as Gilead's recently approved pan-genotypic chronic HCV treatment Epclusa, are now able to offer a cure for more than 90% of people living with hepatitis C.

Gilead’s hepatitis C sales start to slide – the question is how quickly?

Gilead’s hepatitis C sales start to slide – the question is how quickly? Gilead is looking to the future with new universal two-drug regimen Epclusa (sofosbuvir/velpatasvir) - which started to build inventory in the quarter after approval in the US last month - as

Gilead’s universal hep C therapy Epclusa approved in EU

Gilead’s universal hep C therapy Epclusa approved in EU European nod for first pan-genotypic treatment follows recent FDA licensing. Gilead's pan-genotypic hepatitis C virus (HCV) treatment Epclusa has been granted marketing authorisation following an accelerated review procedure ... He added that the pharma

FDA approves Gilead's 'universal' hep C combination Epclusa

FDA approves Gilead's 'universal' hep C combination Epclusa Adds a third Sovaldi-based treatment to the firm’s portfolio. US regulators have approved Gilead's Epclusa (sofosbuvir/velpatasvir) to treat adult patients with chronic hepatitis C virus (HCV) both ... Epclusa joins Sovaldi and Harvoni

Gilead, Merck get CHMP backing for new hep C combinations

Gilead, Merck get CHMP backing for new hep C combinations Approval of Epclusa and Zepatier will see the pan-genotypic drugs compete for market share. ... Epclusa and Zepatier belong to a new generation of medicines for chronic HCV infection, direct-acting antivirals, that give high rates of cure of HCV infection

[ Previous 5 results ] 1 2 3

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics